Software and tech for health care — electronic medical records, hospital booking systems and apps that help doctors track patients and share test results.
Contains
News movingHealth Care Technology
United States
Health Care Technology▲
Nasdaq Panel Reverses Delisting, Approves SCWorx Continued Listing
The Nasdaq Hearings Panel granted SCWorx Corp.'s request for reconsideration and approved the company's continued listing on The Nasdaq Capital Market, reversing the Panel's September 17, 2026 delisting decision. The Panel determined that SCWorx now meets Nasdaq's continued listing requirements, including the minimum bid price rule 5550(a)(2) and the minimum publicly held shares rule 5550(a)(4). Trading in SCWorx common stock on Nasdaq, suspended since April 14, 2026, will be reinstated on a date to be scheduled by Nasdaq, and the stock will continue to be quoted on the OTCQB Venture Market under the symbol WORX until then. The decision followed the company's September 16, 2026 private placement, which together with warrant exercises raised publicly held shares to 549,092 as of September 17, 2026, above the 500,000-share minimum, and the closing bid price has been at or above $1.00 per share every trading day since August 4, 2026. As conditions, the Panel required disclosure that each private placement investor agreed not to exercise its termination right, imposed a Discretionary Panel Monitor for a one-year period ending October 2, 2027, and required monthly reports of shares outstanding, insider holdings and public float through October 5, 2027.
WORX · Regulation · Positive Nasdaq Hearings Panel reversed the delisting and approved SCWorx's continued listing on the Nasdaq Capital Market, reinstating trading.
Servier Selects Veeva OpenData to Standardize Data Across 80-Plus Countries
Veeva Systems announced that Servier has selected Veeva OpenData to standardize customer reference data across more than 80 countries, expanding the French pharmaceutical group's relationship with Veeva beyond its existing use of Veeva Link Key People. The deployment is expected to improve data consistency, connect customer information with actionable insights and support more targeted commercial and medical engagement. Veeva OpenData is one product within Veeva's broader Data Cloud portfolio, which also includes Veeva Link and Veeva Compass, each addressing different aspects of life sciences data requirements. The win could deepen Veeva's footprint within large pharmaceutical organizations and support recurring revenue growth in its Data Cloud business as drugmakers scale artificial intelligence and advanced analytics. Veeva currently has a market capitalization of $44.25 billion, and its shares have gained 22.4% year to date.
Inspire Medical Wins New Category I CPT Codes for Hypoglossal Nerve Stimulation
Inspire Medical Systems announced that the American Medical Association's CPT Editorial Panel approved new Category I CPT codes for procedures involving a single lead and implantable pulse generator, including the company's recent launch of the Inspire V system. The new codes, effective Jan. 1, 2028, establish a dedicated coding framework for hypoglossal nerve stimulation procedures and are expected to create a clearer, more consistent pathway for coding and reimbursement while reducing administrative burden for hospitals and physicians. The company credited support from the American Academy of Otolaryngology-Head and Neck Surgery, the American Academy of Sleep Medicine and the International Surgical Sleep Society in seeking a permanent coding solution. The codes now enter the Medicare valuation process, with the Centers for Medicare & Medicaid Services expected to weigh recommendations from the AMA Relative Value Scale Update Committee; Inspire Medical expects CMS to publish proposed valuations in July 2027 and final valuations in November 2027. Inspire V, a closed-loop implantable device designed to synchronize with patients' natural breathing to help maintain an open airway during sleep, has treated more than 140,000 patients over more than a decade of clinical experience. INSP stock has lost 1.1% since the announcement on Thursday and is down 24.2% year to date, against the industry's 18.4% growth and the S&P 500's 12.3% rise, with a market capitalization of $2.02 billion.
INSP · Regulation · Positive AMA CPT Editorial Panel approved new Category I CPT codes for hypoglossal nerve stimulation, creating a clearer coding and reimbursement pathway for Inspire's procedures and Inspire V system
M3 Forecasts Over 20% Revenue Growth and Higher Operating Profit for Fiscal Year Ending March 2026
M3's full-year results for the fiscal year ending March 2026 showed revenue of 351.3 billion yen, up 23.3% year on year, operating profit of 73.5 billion yen, up 16.8%, and net profit of 49.1 billion yen, up 21.3%, marking the first operating profit increase in four fiscal years and a return to a growth trajectory. Operating profit had fallen for three consecutive fiscal years after peaking at 95.1 billion yen in the fiscal year ended March 2022, but recovered this period. However, the operating margin has declined from 45.7% in the fiscal year ended March 2022 to 20.9%, as revenue grew nearly 70% over four years from 208.1 billion yen to 351.3 billion yen while profit remains below its peak. The main reason for the margin decline is a shift in the business mix as the company has successively taken in businesses with different profitability profiles: its largest earner, the Medical Platform, kept a profit margin of 34.5% on revenue of 104 billion yen, while Patient Solution, which absorbed Ewell after it became a subsidiary in April 2025, saw revenue swell to 56.8 billion yen, 2.6 times the previous year's level, yet its profit margin stood at just 4.7%. For the fiscal year ending March 2027, the company forecasts revenue of 400 billion yen, up 13.8% year on year, operating profit of 80 billion yen, up 8.8%, and net profit of 53 billion yen, up 7.9%.
2413.JP · Capital · Positive M3 reported FY ending March 2026 revenue up 23.3% to 351.3 billion yen and operating profit up 16.8% to 73.5 billion yen, its first profit increase in four years.
E-Well Co., Ltd. (イーウェル) · Capital · Neutral E-Well became an M3 subsidiary in April 2025, swelling Patient Solution revenue 2.6x to 56.8 billion yen but with only a 4.7% profit margin, dragging M3's overall margin.
Veeva Launches Study Builder Agent for Clinical Study Configuration
Veeva Systems announced Veeva Study Builder Agent, a new AI solution that configures Veeva EDC and Veeva DQS directly from a study protocol, enabling clinical studies to be configured in as little as one day. The agent reuses an organization's existing standards and leverages the CDISC Unified Study Definitions Model, or USDM, to deliver faster and more deterministic study builds. It configures EDC forms, visits, and edit check rules, as well as CQL-based listings in DQS, and automates testing, including the generation of test data. Drew Garty, chief technology officer of Veeva Clinical Data, said the agent will make it much faster to build high-quality studies. Planned for early adopter availability in December 2026, Veeva Study Builder Agent is part of EDC and requires no additional license, and it is delivered as a Claude Cowork plugin installed from a Veeva-managed GitHub repository.
Veeva Vault CRM Adds Another Top 20 Biopharma Commitment
Veeva Systems announced a new top 20 biopharma commitment for its Vault CRM, adding to recent selections by Amgen, Biogen, Eli Lilly and Company, and Regeneron. With more than 190 live customers and global commitments from 14 of the top 20 biopharmas, Vault CRM is positioned as the next generation of CRM, delivering new agentic and core capabilities to increase field productivity and effectiveness. The company said Vault CRM serves as a foundation for agentic commercial, helping transform how the industry engages healthcare professionals, with innovations such as the Agentic Call Report generating Commercial Evidence. Arno Sosna, president of CRM Suite at Veeva, said the company is working with customers as Vault CRM drives the shift to agentic commercial, establishing a new way of working that helps bring medicines to patients faster and more efficiently. Vault CRM is part of the Veeva Vault CRM Suite, which connects sales, marketing, and medical for more effective, customer-centric, and compliant engagement across channels.
VEEV · Demand · Positive New top 20 biopharma commitment for Vault CRM, adding to recent selections by Amgen, Biogen, Eli Lilly and Regeneron, with 190+ live customers and 14 of top 20 biopharmas committed.
Doximity Launches Bedside Bench AI Benchmark, Tops Frontier Models in Clinical Testing
Doximity launched Bedside Bench, an open-source benchmark designed to evaluate clinical-grade AI using realistic bedside scenarios, and independent testing by Fireworks ranked its Doximity Ask system ahead of several frontier models. The results reinforce the clinical credibility of Doximity Ask, which the company sees as central to keeping physicians engaged on its platform and attractive to pharma and health system advertisers. The launch arrives alongside a new securities class action that raises nearer-term risk around disclosure practices and ad-driven growth, adding to existing concerns over pharma budget exposure and Newsfeed monetization. Doximity's narrative projects $793.7 million in revenue and $198.5 million in earnings by 2029, requiring 6.6% yearly revenue growth and a $31.5 million earnings increase from $167.0 million today, with a $29.78 fair value implying 12% upside to the current price. Some of the lowest ranked analysts were already projecting only about 4.4 percent annual revenue growth to roughly US$733,800,000 and shrinking margins, a more cautious view that could shift further once Bedside Bench and the new lawsuit are fully reflected.
Amgen Selects Veeva Vault CRM for Global Deployment
Amgen has selected Veeva Systems' Vault CRM for a global deployment, extending a collaboration that has spanned more than a decade. The rollout is expected to support Amgen's commercial operations as it advances new therapies across worldwide markets, with Amgen saying the migration will help accelerate delivery of new therapies with greater speed and agility. The win reinforces Veeva's commercial business, where management recently described fiscal second-quarter 2027 as its best CRM quarter ever, with commercial subscription revenue growing about 13% year over year. Vault CRM now has more than 180 live customers, and management reiterated confidence in maintaining more than 70% market share in life sciences CRM. Veeva currently has a market capitalization of $42.13 billion, and its shares have gained 16.8% year to date.
VEEV · Demand · Positive Amgen selected Veeva's Vault CRM for a global deployment, a concrete customer win extending a decade-long collaboration.
AMGN · Demand · Neutral Amgen selected Veeva Vault CRM for global deployment to support its commercial operations, a software adoption rather than a product-demand event for Amgen itself.
CRM · Competition · Negative Amgen's selection of Veeva Vault CRM is a competitive loss for Salesforce in life-sciences CRM, though Salesforce is not named in the article.
Craneware Shares Fall 24% as Cyberattack and 340B Woes Force FY27 Reset
Craneware shares fell roughly 24% after the Edinburgh-based healthcare software group warned that revenue for the year ending June 2027 is now expected to be around $185 million, roughly in line with its annual recurring revenue base. The reset follows a broadly flat 2026 financial year, in which revenue came in at $206 million versus $205.7 million previously, adjusted EBITDA rose 3% to $67.1 million, the adjusted EBITDA margin improved to 33%, and statutory pretax profit rose 7% to $25.8 million. Annual recurring revenue barely moved at $185 million, while net revenue retention dropped to 100% from 107%. Management blamed growing regulatory uncertainty and increasingly complex requirements from pharmaceutical manufacturers in the US 340B drug-pricing market, which slowed the conversion of identified savings opportunities into transaction revenue. A July cyberattack, disclosed after the financial year ended, added a second blow: hackers gained unauthorized access to part of Craneware's data environment and extracted data, and although core operations continued without disruption and specialists confirmed systems are secure, the company is still determining what data was affected and notifying customers and regulators. Craneware finished the year with $54.8 million of cash and $156 million of undrawn borrowing facilities, and said it has adopted a more cautious planning basis for the next three years, including a comprehensive cost review, with FY27 now effectively a transition year.
Simulations Plus Licenses ADMET Predictor to FDA Cosmetics Regulatory Science Branch
Simulations Plus announced that the U.S. Food and Drug Administration's Cosmetics Regulatory Science Branch has licensed its ADMET Predictor software platform to support computational research for modern cosmetic safety assessment. The contract expands the use of Simulations Plus technology within the FDA and underscores the growing role of predictive modeling and mechanistic science in regulatory research. ADMET Predictor combines artificial intelligence and machine learning with high-throughput pharmacokinetic modeling and predictive ADMET and toxicity assessments, giving FDA researchers a unified computational framework to evaluate both potential exposure and intrinsic hazard. The development supports the FDA's ongoing research into New Approach Methodologies. The announcement builds on Simulations Plus' 2024 research collaboration with the International Collaboration on Cosmetics Safety to evaluate physiologically based kinetic modeling approaches for animal-free safety assessment of cosmetics and other non-pharmaceutical ingredients. Chief Executive Officer Shawn O'Connor said the FDA's adoption expands the company's relationship with one of the world's leading regulatory organizations and highlights the versatility of its technology beyond pharmaceutical research.
SLP · Demand · Positive FDA Cosmetics Regulatory Science Branch licensed Simulations Plus' ADMET Predictor software, a concrete new customer adoption of its product.
DarioHealth Wins New Jersey Health Plan Contract Covering 1.5M Lives
DarioHealth secured a contract with one of New Jersey's largest health plans, representing approximately 1.5 million covered lives, through its channel partnership with Amwell. The program, which covers Dario's cardiometabolic suite and provider-backed care, is expected to launch and begin generating revenue in the first quarter of 2027. The deal marks DarioHealth's third large state health plan contract through Amwell in the past 12 months, following agreements in Arizona and Florida. The stock traded about 4% higher in Thursday pre-market hours.
DRIO · Demand · Positive DarioHealth won a New Jersey health plan contract covering ~1.5M lives for its cardiometabolic suite, its third large state plan deal via Amwell in 12 months.
AMWL · Demand · Positive DarioHealth's new state health plan contract was secured through its channel partnership with Amwell, driving end-customer adoption of Amwell's platform.
SUSMED's Blockchain Clinical Trial System Powers World's First Drug Approval
SUSMED, a Japanese company that develops therapeutic apps and clinical trial support systems, announced on September 16 that a drug tested in a clinical trial using its blockchain-based system has received domestic manufacturing and marketing approval. According to the company's research, this is the world's first drug approval based on the results of a corporate-sponsored clinical trial that used blockchain. The approved drug is Uekix Tablets, indicated for excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea syndrome, among other conditions. Viatris Pharmaceuticals obtained the approval, and SUSMED provided the system for the domestic clinical trial. SUSMED's SourceDataSync uses blockchain technology for data verification, checking whether records of patients' conditions and drug effects match the original records at medical institutions, with the aim of reducing manual confirmation work and data entry at medical institutions while maintaining the reliability of the records. Leading up to this approval, SUSMED conducted verification under the government's regulatory sandbox program, and in December 2020 received a response from the Ministry of Health, Labour and Welfare that blockchain-based data verification could replace conventional work. This was followed by a trial that began in November 2022, and in January 2023 the system was adopted for a trial in a different target disease. The key point this time is that a technology still in the verification stage was used in a clinical trial that led to drug approval, and SUSMED says that a separate comparative study showed a reduction in man-hours for clinical trial confirmation work and other tasks.
4263.JP · Technology · Positive SUSMED's blockchain-based SourceDataSync system was used in the clinical trial that led to the world's first drug approval based on blockchain-verified data, validating its technology.
MindMaze Therapeutics to Launch MindMotion Lite for Home Neurorehabilitation by End of 2026
MindMaze Therapeutics announced the launch of MindMotion Lite by the end of 2026, a tablet-based solution that brings the full range of MindMotion neurotherapeutic activities into the home. The new product delivers all neurotherapeutic activities available on MindMotion GO through a tablet, significantly reducing the hardware requirements for home deployment while retaining full-body rehabilitation capabilities and supporting teleconsultation and remote management. CEO Zach Henderson said the AHA/ASA guidelines updated in August 2026 emphasize sufficient rehabilitation intensity and continuity of care after stroke, yet access to continued neurotherapy after patients return home remains a critical gap, and MindMotion Lite is designed to help close it. The company said the tablet-based format is designed to enhance patient experience, streamline distribution, and reduce home deployment costs compared with MindMotion GO, supporting a more scalable and capital-efficient expansion of its home-based offering. MindMaze Therapeutics will preview MindMotion Lite at upcoming clinical, healthcare and investor conferences, with further details on commercial availability and launch markets to be shared closer to launch.
Coinbase Falls Ahead of Senate CLARITY Act Vote; Waystar Jumps on Sale Report
Coinbase shares slid about 4% and are down roughly 15% year to date as the Senate prepares to vote this afternoon on the CLARITY Act, the crypto regulation bill that needs 60 votes to avoid a filibuster, with Republicans holding 53 seats and needing at least seven Democrats. Other crypto-linked names including Robinhood and Bitcoin investor Strategy also traded lower, while prediction platform Polymarket puts the odds of the CLARITY Act passing at between 18 and 30%, with disputes remaining over ethics rules tied to digital asset holdings, anti-money laundering requirements and stablecoin yields. Separately, Waystar shares rose 11.5% after Reuters reported the hospital and physician payments software provider is exploring options including a sale that would take it private just two years after its New York listing, with Evercore advising and talks still at a very early stage; the stock remains down about 24% this year. Dave & Buster's shares fell 13% after the restaurant and arcade chain reported second-quarter revenue that missed the average analyst estimate, a $12.5 million loss, and a roughly 2.5% revenue decline driven by a nearly 9% drop in entertainment-related sales, with new CEO Darren Harper, about a month into the job, saying he will focus on making the chain a go-to location for special occasions and improving value for guests without giving specifics.
COIN · Regulation · Negative Senate vote on the CLARITY Act crypto regulation bill is imminent and Polymarket odds of passage are only 18-30%, pressuring Coinbase shares.
PLAY · Capital · Negative Dave & Buster's reported Q2 revenue missing estimates, a $12.5 million loss, and a ~2.5% revenue decline driven by a 9% drop in entertainment sales.
WAY · Capital · Positive Reuters reported Waystar is exploring options including a sale to take it private, with Evercore advising, sending shares up 11.5%.
Sysco Falls on $1 Billion Stock Offering; Waystar Gains on Sale Report
Sysco shares fell 1.3% in premarket trading to $82.49 after the foodservice distributor announced late Monday a $1 billion common stock offering to help partially finance its pending acquisition of Jetro Restaurant Depot. The company priced 12.35 million shares at $81 each, a discount of roughly 3% to Monday's closing price of $83.54, with the offering expected to close on September 16 and likely to result in near-term dilution for existing shareholders. Investor concerns were also heightened by the broader financing structure of the $29.1 billion Jetro Restaurant Depot acquisition, which is being funded primarily through about $21 billion of new and hybrid debt, alongside the equity offering. Waystar shares rose 3.3% to $25.73 in premarket trading after reports that the healthcare software company is exploring strategic options, including a potential sale that could take it private again just two years after its initial public offering in 2024. EQT holds the largest stake in Waystar at 13%, followed by the Canada Pension Plan Investment Board with 10% and BlackRock with 8%.
SYY · Capital · Negative Sysco announced a $1 billion discounted stock offering to partly finance the Jetro acquisition, causing near-term dilution for existing shareholders.
WAY · Capital · Positive Waystar is exploring strategic options including a potential sale that could take it private again, lifting its shares.
Certara Swings to $6.1 Million Loss as Software Grows and Services Slip
Certara reported a second-quarter 2026 net loss of $6.1 million, reversing net income of $1.5 million a year earlier, even as its software segment grew. Software revenue rose 4% to $48.8 million and software bookings climbed 9% to $50.7 million, while services revenue fell 3% to $44.5 million and services bookings dropped 6% to $47.6 million. Total revenue reached $93.3 million, up 1% from $92.4 million, and management reaffirmed full-year revenue guidance of $367 million to $382 million, or growth of 0% to 4%. The quarter included a workforce reduction touching about 5% of the global workforce, expected to generate roughly $13 million in annualized savings, following the May 8 sale of the Regulatory and Medical Writing business and the creation of two business units in May. Certara spent $17.4 million to complete its $100 million share repurchase program in the quarter, and the board approved an additional $50 million for buybacks in the third quarter; Julien Perrier became Chief Commercial Officer effective August 1, 2026. Diluted loss per share was $0.04, adjusted EBITDA fell 3% to $26.2 million, and operating expenses rose to $58.3 million from $50.4 million.
Phreesia Posts $129.5 Million Quarter, Flags Client Strain
Phreesia reported second-quarter fiscal 2027 results for the period ended July 31, with revenue climbing to $129.5 million and adjusted EBITDA surging to $32.9 million. The healthcare technology company posted its fifth straight quarter of positive net income and its ninth straight quarter of positive operating cash flow, as revenue rose 10% year over year and average healthcare services clients reached 4,744, up 6%, with total revenue per client climbing 4% to $27,289. Adjusted EBITDA jumped $10.8 million year over year, pushing margin to 25%, while net income hit $1.9 million, operating cash flow reached $18.3 million and free cash flow $13.8 million. That cash, combined with existing reserves, let Phreesia retire more than $23 million in debt principal during the quarter, and management pointed to a May restructuring plan that eliminated 220 positions, about half of them contractor roles, at an estimated total cost of $10 million, of which $2.8 million was recognized this quarter. CFO Balaji Gandhi warned there is now more variability in network solutions revenue forecasting, particularly in the second half of each fiscal year, and CEO Chaim Indig described healthcare providers as under a significant amount of strain, with total revenue per client falling about 2% sequentially and total revenue dipping roughly 1% from the first quarter. Phreesia reaffirmed its $510 million to $520 million revenue outlook and its $125 million to $135 million adjusted EBITDA outlook for fiscal 2027.
PHR · Capital · Neutral Q2 FY2027 revenue $129.5M, adjusted EBITDA $32.9M, fifth straight positive net income, debt paydown and reaffirmed guidance, but CFO flags network-solutions revenue variability and CEO cites client strain with revenue per client down 2% sequentially.
Accuray and RaySearch Expand Collaboration on Online Adaptive Radiation Therapy
Accuray Incorporated and RaySearch Laboratories AB have entered into a definitive agreement for an expanded collaboration aimed at accelerating Accuray's adoption of online adaptive radiation therapy. The collaboration combines Accuray's photon-based radiation therapy platforms and imaging capabilities with RaySearch's treatment planning and workflow software, with the initial focus on Accuray's Radixact platform and future extension to the CyberKnife platform. Under the agreement, Accuray has agreed to purchase specified RayStation licenses with a total order value of USD $8 million to support commercialization of online adaptive radiation therapy solutions, which the two parties will jointly market and support. The collaboration will also leverage RayCare technology to simplify connectivity between clinical systems, and RaySearch will further enhance its software to support the Radixact platform. RaySearch founder and CEO Johan Löf said Accuray's global presence, large installed base, differentiated technology and worldwide service capabilities made them an ideal partner, while Accuray CEO Steve LaNeve said the partnership supports the company's growth strategy and its online adaptive radiation therapy strategy.
0GRZ.LSE · Demand · Positive RaySearch secures an $8M order for RayStation licenses and expands its software collaboration with Accuray for online adaptive radiation therapy.
ARAY · Demand · Positive Accuray enters expanded collaboration with RaySearch and orders $8M in RayStation licenses to accelerate commercialization of online adaptive radiation therapy on its Radixact platform.
Health Catalyst Names Simeon Kohl CEO and President
Health Catalyst, Inc. has appointed Simeon Kohl as Chief Executive Officer and President, effective September 14, 2026, and he will also join the Board of Directors. Kohl previously led Performant Healthcare through a transformation that culminated in its sale to Machinify for approximately $670 million. Current CEO and President Ben Albert will transition to Chief Business Officer and step down from the Board on September 13, 2026. Albert's tenure included divesting Vitalware, which helped retire the company's approximately $160 million credit facility. Kohl cited Health Catalyst's $2.8 billion in documented outcomes as a key attraction to the role.
HCAT · · Neutral Health Catalyst appoints Simeon Kohl as CEO/President, a leadership change with no clear positive or negative operational driver stated.
Performant Healthcare · · Neutral Referenced only as the prior company Kohl led through a transformation and sale to Machinify.
Veeva Systems Expands AI Offerings with Regeneron and Biogen Deals
Veeva Systems announced that Regeneron and Biogen have adopted its AI-powered Vault CRM suite globally, and introduced Veeva Falcon Safety, a new agentic safety operations product for biopharma clients. These moves expand Veeva's AI-focused offerings across commercial and safety workflows in life sciences, reinforcing its position as a key provider of industry-specific cloud software. With a market cap of about $45.5 billion, Veeva is a large specialist in healthcare software, and these global commitments signal deeper integration of its AI tools into core biopharma operations, potentially increasing switching costs and making multi-year relationships more durable. The company plans a November 2026 rollout for Falcon Safety, and investors will watch for early adopters and quantified updates in upcoming earnings calls to gauge traction.
Veeva Raises FY27 Outlook as Vault CRM and AI Momentum Accelerate
Veeva Systems raised its fiscal 2027 outlook after second-quarter revenues increased 17.6% year over year to $928 million, driven by Vault CRM adoption and broader commercial execution. The company now expects fiscal 2027 revenues of $3.682-$3.687 billion, subscription revenues of about $3.08 billion, and adjusted earnings of roughly $9.21 per share, implying about 15% growth at the high end. Management also projects approximately $1.64 billion in non-GAAP operating income, with a roughly 44% non-GAAP operating margin. Vault CRM recorded its best quarter to date, with two additional top-20 biopharma selections, bringing commitments to 12 of the top 20, and more than 180 customers are live on the platform. Falcon, Veeva's agentic AI product, has five early adopters including a top-20 pharma company, with first go-lives expected in 2026, though monetization remains early. R&D and Quality subscription revenues rose 19% year over year to $419.4 million in the second quarter, as newer products like EDC, eCOA, RTSM, Safety, and LIMS are expected to become more important. Veeva currently carries a Zacks Rank #3 (Hold), with a Value Score of D, a Growth Score of B, a Momentum Score of A, and a VGM Score of B.
Phreesia Q2 Revenue Misses Estimates, EPS Falls Short
Phreesia reported second-quarter revenue of $129.46 million, up 10.4% year over year, but slightly below the Zacks Consensus Estimate of $129.63 million, while EPS of $0.03 missed the consensus estimate of $0.11. Among key metrics, average healthcare services clients came in at 4,744 versus the estimated 4,747, and total managed payments reached $1.63 billion against the $1.76 billion estimate. Subscription and related services revenue fell 1.9% to $52.7 million, slightly below the $52.98 million estimate, while network solutions revenue of $38.27 million beat the $35.58 million estimate, and payment solutions revenue of $38.49 million missed the $40.46 million estimate. Shares have gained 3.5% over the past month, outperforming the S&P 500's 2% rise, and the stock holds a Zacks Rank #3 (Hold).
Phreesia reported second-quarter earnings of $0.03 per share, missing the Zacks Consensus Estimate of $0.11 per share, and compared to $0.01 per share a year ago. Revenue for the quarter ended July 2026 was $129.46 million, slightly below the consensus estimate of $129.63 million, but up from $117.25 million in the prior-year period. The company has beaten earnings estimates in three of the last four quarters. Phreesia shares have fallen about 30% since the start of the year, while the S&P 500 has gained 11.5%. The company's stock currently carries a Zacks Rank #3 (Hold), indicating expectations of in-line performance with the market in the near term.
Median Technologies Forms Strategic Review Committee to Unlock Value
Median Technologies has announced the formation of a Strategic Review Committee to evaluate a range of strategic alternatives, including a potential separation of its iCRO business, a potential U.S. listing, and other options, aiming to unlock intrinsic value and accelerate its eyonis pan-cancer strategy. The company also established a dedicated R&D Committee to oversee its scientific roadmap. The move follows recent milestones such as FDA clearance and CE marking for eyonis LCS, a distribution partnership with Tempus AI, and a 50 million euro capital raise. Median's board believes its current valuation does not reflect the growth potential of its eyonis and iCRO businesses, which have a record order backlog of 82.4 million euros as of June 30, 2026. No decision has been made yet, and the committee will engage independent advisors to support its work.
ALMDT.PA · Capital · Positive Forms Strategic Review Committee to evaluate separation of iCRO business and a potential U.S. listing to unlock value, citing valuation below growth potential.
Definitive Healthcare Receives Going-Private Proposal from Advent International
The special committee of Definitive Healthcare's board has confirmed receipt of a non-binding proposal from Advent International to acquire all outstanding shares of Class A common stock and Definitive OpCo Units not already owned by Advent or founder Jason Krantz, for $1.02 per share in cash. The special committee, composed of independent directors, will review the proposal with its advisors to determine the best course for the company and its stockholders. No action is required from stockholders at this time, and there is no assurance that a transaction will be pursued or completed. Rothschild & Co and Skadden, Arps are advising the special committee, while Evercore and Hogan Lovells Cadwalader are advising the company.
Definitive Healthcare surges on Advent International buyout offer
Definitive Healthcare shares rose 14% in premarket trading after private equity firm Advent International made a non-binding offer to acquire the company for $1.02 per share in an all-share deal. Advent, which already owns 62.5 million Class A shares representing nearly a 59% stake, values the SaaS provider at a 36% premium to its 60-day volume-weighted average price of $0.75 per share as of August 31. The transaction, not subject to financing conditions, will see founder and executive chairman Jason Krantz roll his equity into the new entity. Concurrently, Definitive Healthcare announced Clay Ritchey, former CEO of Verato, will become its next chief executive and board member effective September 8, succeeding Kevin Coop, who departed on August 31 after more than two years.
DH · Capital · Positive Advent International made a non-binding all-share buyout offer at $1.02 per share, a 36% premium to the 60-day VWAP.
Advent International · Capital · Neutral Advent International is the acquirer making the non-binding offer for Definitive Healthcare, but the article does not assess the deal's impact on Advent itself.
Definitive Healthcare Names Clay Ritchey as New CEO
Definitive Healthcare Corp., a leader in healthcare market data and analytics, has appointed Clay Ritchey as its next Chief Executive Officer and a member of the Board of Directors, effective September 8, 2026. Ritchey, who brings over 25 years of healthcare expertise, succeeds Kevin Coop, who departed as CEO and board member on August 31, 2026, after serving since June 2024. Ritchey joins from Verato, a healthcare master data management company, where he was CEO, and has held senior roles at Evariant, Imprivata, Equinox Healthcare, Hill-Rom, and Kronos. Chairman Jason Krantz praised Ritchey's track record of driving profitable growth and his conviction that AI will reshape healthcare, positioning Definitive Healthcare as a leader in commercial intelligence. Ritchey expressed excitement about accelerating the company's return to growth, citing its proprietary datasets and upcoming AI-powered platform.
Veeva Falcon Safety to Support All E2B-Compliant Safety Systems
Veeva Systems announced Veeva Falcon Safety, an agentic safety operations product designed to streamline adverse event intake, case processing, and follow-up for biopharma companies. Falcon Safety will work with any E2B-compliant safety system, including Oracle Argus and ArisGlobal LifeSphere MultiVigilance, in addition to Veeva Safety. The product is planned for early adopter availability in November 2026 and is part of Veeva AI, the company's industry-specific AI solutions for life sciences. Marius Mortensen, vice president of product for Falcon at Veeva, said the product builds on Veeva's partnership with case processors and pharmacovigilance experts to help reinvent safety operations.
Profusa Regains Compliance with Nasdaq Publicly Held Shares Rule
Profusa, Inc. announced that it has received a notice from Nasdaq stating that after its 1-for-4 reverse stock split on August 14, 2026, it fell below the required 500,000 publicly held shares, but following correspondence on August 21, 2026, Nasdaq determined the company complies with the rule and has closed its review. The notice does not affect the listing or trading of Profusa's securities, which continue on the Nasdaq Capital Market under the symbol PFSA. The company made the announcement in accordance with Nasdaq Listing Rule 5810(b), which mandates prompt disclosure of deficiency notifications. Profusa, based in Berkeley, California, develops tissue-integrated biosensors for medical and personal use.
PFSA · Regulation · Positive Nasdaq determined Profusa regained compliance with the 500,000 publicly held shares rule after its reverse split, closing the deficiency review.
B-Soft's 2026 interim report shows net loss of 197 million yuan, widening year-on-year
B-Soft released its 2026 interim report. Total operating revenue was 455 million yuan, down 21.15% year-on-year. Net profit attributable to the parent company was negative 197 million yuan, a decrease of 117 million yuan compared with the same period last year, with the loss widening. Net cash flow from operating activities was negative 451 million yuan, a year-on-year decrease of 274 million yuan. The company's asset-liability ratio was 22.36%, gross margin was 34.70%, return on equity was negative 5.16%, and diluted earnings per share was negative 0.13 yuan. The number of shareholders was 53,300, and the top ten shareholders held 29.63% of total share capital.
B-Soft Swings to a Loss of Nearly 200 Million Yuan in the First Half as Strategy Faces Adjustment After Controlling Shareholder Change
B-Soft disclosed its first half-year report following the change in controlling shareholder. Revenue for the first half was 455 million yuan, down 21.15 percent year on year. Net profit attributable to the parent swung from profit to a loss of 197 million yuan, a year-on-year decline of 144.74 percent. Net profit after deducting non-recurring items was a loss of 204 million yuan, down 115.83 percent year on year. The company said the healthcare IT industry is in a deep structural adjustment cycle, with local fiscal budgets tightening, project tenders delayed, and acceptance periods lengthened, leading to a decline in recognized revenue. In addition, the new controlling shareholder Hangzhou Genghao may push for organizational restructuring and strategic transformation, creating uncertainty in the short term. In the secondary market, B-Soft's latest closing price was 3.54 yuan per share, a decline of about 27 percent this year.
300451.CS · Capital · Negative B-Soft swung to a 197 million yuan first-half loss with revenue down 21.15% year on year.
300451.CS · Demand · Negative Healthcare IT structural adjustment, tightening local fiscal budgets, delayed tenders and longer acceptance periods cut recognized revenue.
300451.CS · Regulation · Neutral New controlling shareholder Hangzhou Genghao may push organizational restructuring and strategic transformation, creating short-term uncertainty.
杭州更好智投管理咨询合伙企业(有限合伙) · · Neutral Named as the new controlling shareholder that may push restructuring and strategic transformation, with no concrete action stated.
Veeva's 40% GAAP Operating Income Growth Not a Clean Run Rate
Veeva Systems reported fiscal second-quarter revenue of $928 million, up 18% year over year, with subscription revenue rising 16% to $766.8 million and GAAP operating income climbing 40% to $275 million, lifting the operating margin to 29.6% from 24.8%. However, the prior-year quarter included a $30.6 million litigation settlement charge, and excluding that item would put the earlier margin near 28.7%, making the underlying expansion closer to one percentage point. Subscription growth remains strong, with more than 180 customers live on Vault CRM and 12 of the top 20 biopharmaceutical companies committed to the platform, while the company added over 30 clinical customers and surpassed 100 Veeva Safety customers. Non-GAAP operating income rose 18% to $415.9 million, with the margin edging up to 44.8% from 44.7%, but operating cash flow was nearly flat at $238.7 million and professional-services gross margin declined to 31.5% from 33.4%. For fiscal 2027, Veeva expects revenue of $3.682 billion to $3.687 billion and non-GAAP operating income of about $1.64 billion, implying a margin of approximately 44.5%, which management characterized as about 44%, suggesting continued high profitability but not obvious expansion from fiscal 2026's 44.9%.
Teladoc Health's shares have fallen 3.3% since its second-quarter 2026 earnings report, underperforming the S&P 500. The company reported an adjusted loss of 21 cents per share, beating the Zacks Consensus Estimate of a 24-cent loss, but revenue declined 4% year over year to $606.9 million, missing estimates. Strength in the Integrated Care segment and international revenues was offset by weakness in BetterHelp and declining access fees. For the full year, Teladoc lowered its revenue guidance to $2.362-$2.447 billion from a prior range of $2.481-$2.576 billion, while adjusted EBITDA guidance was narrowed to $271-$303 million. The stock carries a Zacks Rank #3 (Hold), with estimates trending downward.
Veeva Systems Shares Jump 17% on Strong Q2 Results and Raised Guidance
Veeva Systems shares surged 17% in afternoon trading after the company reported second-quarter financial results that beat Wall Street expectations for revenue and adjusted earnings. The life sciences cloud software provider posted revenue of $928 million, up 17.6% year over year, surpassing the consensus estimate of $905.3 million, while adjusted earnings came in at $2.35 per share, above the projected $2.22. Adjusted operating income reached $415.9 million, ahead of the expected $394.8 million. The company also raised its full-year revenue guidance to $3.68 billion at the midpoint and increased its full-year adjusted earnings outlook to $9.21 per share, citing strong customer momentum in its Vault CRM platform and rapid adoption of its AI offering, Veeva Falcon. At $285.51 per share, the stock is up 30.1% year to date and trading near its 52-week high of $306.22.
Veeva Systems reported second-quarter revenue of US$927.96 million, up from US$789.08 million a year earlier, with net income of US$273.43 million and diluted earnings per share of US$1.66, beating analyst expectations. The company also raised its full-year guidance, projecting total revenue between US$3.68 billion and US$3.69 billion for the fiscal year ending January 31, 2027. Management highlighted AI as a key driver across Veeva Falcon and the broader Vault AI suite. Following the earnings beat, the stock surged 15.2% in one day and 40.22% over 30 days, reaching US$282.13, though the one-year total shareholder return stands at 3.6% and the five-year return is negative 10.7%. The narrative fair value is US$383.14, suggesting a 26.4% undervaluation, but the current P/E of 45.2x exceeds both the industry average of 27.9x and a fair ratio of 32x, indicating limited room for error if growth expectations ease.
Veeva Systems Beats Q2 Estimates, Raises Full-Year Guidance
Veeva Systems reported second-quarter revenue of $928 million, up 17.6% year over year and ahead of the $905.3 million analysts expected, while adjusted earnings per share of $2.35 beat the consensus estimate of $2.22 by 5.8%. The company raised its full-year revenue guidance to $3.68 billion at the midpoint, up from $3.64 billion, and lifted its adjusted EPS guidance to $9.21, a 1.8% increase. Management attributed the strong quarter to robust demand for its CRM solutions and rapid adoption of its new Falcon AI platform, with CEO Peter Gassner calling it the company's best CRM quarter ever. The company also highlighted win-back opportunities in CRM and continued expansion of its R&D cloud suite, while CFO Brian Van Wagener noted that investments in Falcon and other early-stage products will be paced to revenue growth. Veeva's adjusted operating income came in at $415.9 million, beating estimates, and billings rose 17.1% year over year to $760.9 million.
B-Soft's first-half net loss widens to 197 million yuan
B-Soft released its 2026 interim report, showing its first-half net loss widened to 197 million yuan, compared with a loss of 80.55 million yuan in the same period last year. Operating revenue was 455 million yuan, down 21.2 percent year on year. Net loss attributable to shareholders after deducting non-recurring items was 204 million yuan, compared with a loss of 94.62 million yuan a year earlier. Net operating cash flow was negative 451 million yuan, down 153.8 percent year on year. In the second quarter, operating revenue was 257 million yuan, down 10.1 percent year on year, while net loss attributable to shareholders was 118 million yuan, compared with a loss of 64.91 million yuan in the same period last year. As of the end of the second quarter, total assets stood at 5.002 billion yuan, down 5.2 percent from the end of the previous year, and net assets attributable to shareholders were 3.817 billion yuan, down 4.8 percent from the end of the previous year. The company's business is mainly focused on healthcare information technology, and it is accelerating its transformation into an intelligent cloud ecosystem enterprise, with applications such as AI-assisted diagnosis and treatment already in place.
Langma Information swings to loss in 2026 interim report with net loss of 4.99 million yuan
Langma Information released its 2026 interim report. Total operating revenue was 124 million yuan, down 18.20% year on year. Net profit attributable to the parent company was a loss of 4.99 million yuan, a decrease of 19.42 million yuan compared with the same period last year, down 134.56% year on year, swinging from profit to loss. Net cash inflow from operating activities was 6.17 million yuan, down 57.94% year on year. The company's asset-liability ratio was 17.11%, gross margin was 26.30%, return on equity was negative 0.46%, and diluted earnings per share was negative 0.01 yuan.
Nvidia surged 9% after second-quarter revenue and earnings beat expectations, with adjusted earnings of $2.22 per share on $96.22 billion in revenue, surpassing analyst estimates of $2.10 per share and $92.17 billion, and the company forecast third-quarter revenue of $108 billion. Salesforce soared 21% after adjusted earnings of $5.90 per share beat an LSEG estimate of $3.27, while Okta jumped over 27% on better-than-expected results and raised guidance. Veeva Systems climbed 16% on strong quarterly results and upbeat guidance, but HP fell 4% despite beating revenue estimates due to concerns over memory costs and margins. Moderna dropped 4% after proposing a $2 billion convertible notes sale, Celsius fell nearly 6% on a Deutsche Bank downgrade, and Wendy's tumbled 13% after reports that Trian Fund Management won't pursue a buyout. Dollar General rose 5% after raising full-year guidance, while Dollar Tree, Burlington Stores, Best Buy, and Hormel Foods declined on various earnings-related concerns.
Veeva Systems Beats Q2 Estimates, Raises FY27 Outlook
Veeva Systems reported adjusted earnings per share of $2.35 for the second quarter of fiscal 2027, up 18.1% year over year and beating the Zacks Consensus Estimate by 5.9%. Revenue rose 17.6% to $928 million, also topping consensus by 2.7%, driven by strength in subscription and professional services. The company raised its fiscal 2027 revenue guidance to between $3.682 billion and $3.687 billion and adjusted EPS to approximately $9.21. Vault CRM ended the quarter with more than 180 customers live, including five top 20 biopharmas, and the company advanced its AI strategy with Veeva Falcon and the acquisition of Copli. Shares surged over 9% in after-market trading following the announcement.
United States
